deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT01359592

S1001 PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)

Sponsor: National Cancer Institute (NCI)

Conditions Lymphoma
Interventions R-CHOP regimen cyclophosphamide doxorubicin hydrochloride fludeoxyglucose F 18 laboratory biomarker analysis prednisone rituximab selective external radiation therapy vincristine sulfate yttrium Y 90 ibritumomab tiuxetan
Updated 18 times since 2017 Last updated: May 29, 2025 Started: Sep 30, 2011 Primary completion: Jun 3, 2020 Completion: Dec 31, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Lymphoma, this trial is completed. The trial is conducted by National Cancer Institute (NCI) and has accumulated 18 data snapshots since 2011. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Oct 2017 · 9 months · monthly snapshot~Oct 2017 – ~Jun 2018 · 8 months · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Nov 2019 · 12 months · monthly snapshot~Nov 2019 – ~Jul 2020 · 8 months · monthly snapshot~Jul 2020 – ~Sep 2020 · 2 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Aug 2023 · 3 months · monthly snapshot~Aug 2023 – ~Jan 2024 · 5 months · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Jul 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Jul 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 13 earlier versions

  1. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Aug 2023 — Jan 2024 [monthly]

    Active Not Recruiting PHASE2

  3. May 2023 — Aug 2023 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Sep 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE2

  6. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE2

  7. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE2

  8. Jul 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE2

  9. Nov 2019 — Jul 2020 [monthly]

    Active Not Recruiting PHASE2

  10. Nov 2018 — Nov 2019 [monthly]

    Active Not Recruiting PHASE2

  11. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE2

  12. Oct 2017 — Jun 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  13. Jan 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

    First recorded

Sep 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • SWOG Cancer Research Network
Data source: SWOG Cancer Research Network

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anacortes, United States , Anchorage, United States , Ann Arbor, United States , Atlanta, United States , Aurora, United States , Austell, United States , Beech Grove, United States , Bellingham, United States , Billings, United States , Bloomington, United States and 145 more locations